The US Food and Drug Administration (FDA) has approved GE Healthcare’s Cysview to detect non-muscle-invasive papillary bladder cancer in patients with known or suspected bladder cancer.
The optical imaging agent, which has a blue as well as a white light setting, demonstrated an improved rate of detection of non-muscle-invasive papillary cancer compared to standard white light cystoscopy alone, according to Phase III clinical data.
According to the National Cancer Institute, over 70,000 people in the US were diagnosed with cancer of the bladder in 2009, with an estimated 14,000 deaths.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData